Literature DB >> 20956077

"Should I stay or should I go?" Coming off methadone and buprenorphine treatment.

Adam R Winstock1, Nicholas Lintzeris, Toby Lea.   

Abstract

BACKGROUND: This study aimed to investigate patient perspectives regarding coming off maintenance opioid substitution treatment (OST). The study explored previous experiences, current interest and concerns about stopping treatment, and perceptions of how and when coming off treatment should be supported.
METHODS: A cross-sectional survey was used. Participants were 145 patients receiving OST at public opioid treatment clinics in Sydney, Australia.
RESULTS: Sixty-two percent reported high interest in coming off treatment in the next 6 months. High interest was associated with having discussed coming off treatment with a greater number of categories of people (OR=1.72), not citing concern about heroin relapse (OR=3.18), and shorter duration of current treatment episode (OR=0.99). Seventy-one percent reported previous withdrawal attempts and 23% had achieved opioid abstinence for ≥3 months following a previous withdrawal attempt. Attempts most commonly involved jumping off (59%), and doctor-controlled (52%) or self-controlled (48%) gradual reduction. For future attempts respondents were most interested in doctor-controlled (68%) or self-controlled (41%) gradual reduction. Concerns regarding coming off treatment included withdrawal discomfort (68%), increased pain (50%), and relapse to heroin use (48%).
CONCLUSION: While some patients may require lifetime maintenance, the issue of coming off treatment is important to many patients and should be discussed regularly throughout treatment and where appropriate supported by a menu of clinical options. Crown
Copyright © 2010. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956077     DOI: 10.1016/j.drugpo.2010.08.001

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  24 in total

1.  Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.

Authors:  Cheryl Teruya; Robert P Schwartz; Shannon Gwin Mitchell; Albert L Hasson; Christie Thomas; Samantha H Buoncristiani; Yih-Ing Hser; Katharina Wiest; Allan J Cohen; Naomi Glick; Petra Jacobs; Paul McLaughlin; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

2.  Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.

Authors:  Zoe M Weinstein; Gabriela Gryczynski; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong W Kim; Colleen Labelle; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2018-06-19       Impact factor: 4.492

3.  Preliminary findings on the association between clients' perceived helpfulness of substance abuse treatment and outcomes: does race matter?

Authors:  LaTrice Montgomery; Blair Sanning; Nicole Litvak; Erica N Peters
Journal:  Drug Alcohol Depend       Date:  2014-04-05       Impact factor: 4.492

4.  Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support.

Authors:  Dharushana Muthulingam; Joshua Bia; Lynn M Madden; Scott O Farnum; Declan T Barry; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2019-01-26

5.  The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use.

Authors:  Andrew S Huhn; D Andrew Tompkins; Kelly E Dunn
Journal:  Drug Alcohol Depend       Date:  2017-09-09       Impact factor: 4.492

6.  Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance Therapy.

Authors:  Brandon S Bentzley; Kelly S Barth; Sudie E Back; Garrett Aronson; Sarah W Book
Journal:  J Subst Abuse Treat       Date:  2015-04-07

7.  Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement.

Authors:  Scott P Stumbo; Bobbi Jo H Yarborough; Dennis McCarty; Constance Weisner; Carla A Green
Journal:  J Subst Abuse Treat       Date:  2016-11-15

8.  Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.

Authors:  Hillary Samples; Arthur Robin Williams; Mark Olfson; Stephen Crystal
Journal:  J Subst Abuse Treat       Date:  2018-09-07

Review 9.  Recommendations for Substance Abuse and Pain Control in Patients with Chronic Pain.

Authors:  Nalini Vadivelu; Alice M Kai; Gopal Kodumudi; Dan Haddad; Vijay Kodumudi; Niketh Kuruvilla; Alan David Kaye; Richard D Urman
Journal:  Curr Pain Headache Rep       Date:  2018-03-19

10.  Leaving buprenorphine treatment: patients' reasons for cessation of care.

Authors:  Jan Gryczynski; Shannon Gwin Mitchell; Jerome H Jaffe; Kevin E O'Grady; Yngvild K Olsen; Robert P Schwartz
Journal:  J Subst Abuse Treat       Date:  2013-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.